Role of T Regulatory Cells in Chronic HCV Infected Egyptian Patients and Their Impact on the Response to Pegylated Interferon Therapy
(PEG-IFN) and ribavirin achieves overall response (SVR) rates of ~55 %. A role of CD4+ CD25 + regulatory T cells (Treg cells) has been proposed as they can suppress HCV-specific T cells in HCV-infected patients. Patients with chronic HCV legible for PEG-IFN plus ribavirin treatment, were classified...
Gespeichert in:
Veröffentlicht in: | Journal of the Egyptian Society of Parasitology 2015-08, Vol.45 (2), p.345-355 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | (PEG-IFN) and ribavirin achieves overall response (SVR) rates of ~55 %. A role of CD4+ CD25 +
regulatory T cells (Treg cells) has been proposed as they can suppress HCV-specific T cells in
HCV-infected patients. Patients with chronic HCV legible for PEG-IFN plus ribavirin treatment,
were classified according to their response to treatment into two groups (responders and nonresponders,
32 and 27 patients respectively). Blood and plasma samples were collected at the
start of treatment and at 12 and 24 weeks during treatment. Immunophenotyping by flow cytometry
for Treg cells, the FOXP-3 expression using real-time PCR and measurement of IL-10,
TGF-β CXCL-9 and CXCL-10 were performed. Increased expression of Treg cells was detected
in patients who didn't respond to treatment before and during treatment. Also, the levels of IL-
10, TGF-β, CXCL-9 and CXCL-10 revealed significant increase in non-responders all through
compared to responders group. Evaluation of Treg cells, cytokines (IL-10 & TGF-β) and chemokines
(CXCL-9 & CXCL-10) before starting the treatment could be a predictor of response to
treatment with PEG-IFN plus ribavirin. The optimum levels which would differentiate between
responders and non-responders are needed to be defined before- hand |
---|---|
ISSN: | 1110-0583 2090-2549 |
DOI: | 10.12816/0017578 |